| Not Yet Recruiting | Radical CystEctomy or RaDio-chEMotherapy as Preferred Treatment for invasivE blaDder Cancer NCT07008833 | Brazilian Clinical Research Institute | N/A |
| Recruiting | A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder C NCT07475806 | Astellas Pharma Global Development, Inc. | Phase 2 |
| Not Yet Recruiting | Remodeling of MHC-related Immune Microenvironment in MIBC After Neoadjuvant Therapy NCT07440901 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | — |
| Recruiting | Effect of Neoadjuvant Chemotherapy on MRI Accuracy Before Cystectomy NCT07202819 | Assiut University | N/A |
| Recruiting | Sample Collection for Ongoing Research and Product Evaluation Study NCT07318051 | Natera, Inc. | — |
| Recruiting | Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for NCT06916494 | First Affiliated Hospital of Chongqing Medical University | Phase 1 |
| Not Yet Recruiting | Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer NCT06957561 | Sun Yat-sen University | Phase 1 / Phase 2 |
| Not Yet Recruiting | Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ NCT06686381 | American University of Beirut Medical Center | Phase 2 |
| Not Yet Recruiting | Sasanlimab As Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categor NCT06623162 | Fundación de investigación HM | Phase 2 |
| Recruiting | Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence NCT06682728 | University of California, Irvine | Phase 2 |
| Withdrawn | Clinical Performance Evaluation of the C2i Test NCT05860543 | University of Texas Southwestern Medical Center | — |
| Recruiting | Prediction of Therapeutic Response to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer Patients Usin NCT06373055 | Yonsei University | — |
| Recruiting | mpMRI Compared to Diagnostic TURBT in Patients With Suspected Muscle-Invasive Bladder Cancer NCT06335667 | University of California, Irvine | N/A |
| Recruiting | Multi-parametric MRI in Patients Suspected for Muscle Invasive Bladder Cancer: a New Local Staging Paradigm NCT05779631 | Radboud University Medical Center | N/A |
| Unknown | RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC NCT05979740 | RenJi Hospital | Phase 2 |
| Completed | Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER NCT05945108 | AstraZeneca | — |
| Recruiting | Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibr NCT06511648 | Spanish Oncology Genito-Urinary Group | Phase 2 |
| Unknown | To Better Understand the Most Important Factors for Patients When They Decide on the Type of Treatment They Re NCT05236218 | King's College London | — |
| Unknown | A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tisl NCT04813107 | Jiangsu Yahong Meditech Co., Ltd aka Asieris | Phase 1 / Phase 2 |
| Active Not Recruiting | Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin NCT04960709 | AstraZeneca | Phase 3 |
| Recruiting | Multi-parametric MRI in Patients of Bladder Cancer NCT06362330 | The First Affiliated Hospital with Nanjing Medical University | — |
| Active Not Recruiting | A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Blad NCT04660344 | Hoffmann-La Roche | Phase 3 |
| Unknown | Gender-related Characteristics of Bladder Cancer Treatment NCT04687254 | University of Florence | — |
| Unknown | Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma NCT04730219 | Tianjin Medical University Second Hospital | Phase 2 |
| Completed | A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Partic NCT04209114 | Bristol-Myers Squibb | Phase 3 |
| Completed | A Novel Pathway to Detect Muscle-invasive Bladder Cancer Based on Integrated Clinical Features and VI-RADS Sco NCT06807008 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Unknown | Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma NCT04099589 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Unknown | Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer NCT04101812 | Tianjin Medical University Second Hospital | Phase 2 |
| Withdrawn | Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR Study NCT03832673 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 2 |
| Unknown | Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma NCT04047693 | Pusan National University Yangsan Hospital | Phase 2 |
| Completed | A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLA NCT03773666 | Dana-Farber Cancer Institute | Phase 1 |
| Terminated | Avelumab and Radiation in Muscle-Invasive Bladder Cancer NCT03747419 | Dana-Farber Cancer Institute | Phase 2 |
| Active Not Recruiting | Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With NCT03732677 | AstraZeneca | Phase 3 |
| Active Not Recruiting | A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed NCT03661320 | Bristol-Myers Squibb | Phase 3 |
| Terminated | Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplati NCT03234153 | Insel Gruppe AG, University Hospital Bern | Phase 2 |
| Terminated | Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma NCT03397394 | pharmaand GmbH | Phase 2 |
| Completed | BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle I NCT03294304 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer NCT04053101 | Institut Bergonié | — |
| Active Not Recruiting | Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cance NCT02546661 | AstraZeneca | Phase 1 |
| Completed | Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder St NCT02462239 | Ontario Clinical Oncology Group (OCOG) | N/A |
| Terminated | Radical Cystectomy Compared With Chemoradiation for Muscle Invasive Bladder Cancer NCT02716896 | The University of Texas Health Science Center at San Antonio | N/A |
| Unknown | Basal Like Bladder Cancer : Signature and Therapeutic NCT02648100 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | Dose Dense MVAC for Muscle Invasive Bladder Cancer NCT01031420 | Fox Chase Cancer Center | Phase 2 |
| Completed | Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma NCT00808639 | Dana-Farber Cancer Institute | Phase 2 |